deltatrials
Unknown PHASE1/PHASE2 NCT04506138

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Sponsor: Zhejiang Cancer Hospital

Conditions Esophageal Squamous Cell Carcinoma
Interventions Camrelizumab Carboplatin Paclitaxel for Injection (Albumin Bound)
Updated 7 times since 2020 Last updated: Dec 12, 2021 Started: Aug 11, 2020 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025

This PHASE1/PHASE2 trial investigates Esophageal Squamous Cell Carcinoma and is currently ongoing. Zhejiang Cancer Hospital leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Feb 2026 — Present [monthly]

    Unknown PHASE1/PHASE2

    Status: Active Not Recruiting → Unknown

  2. Sep 2024 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Mar 2021 — Jan 2022 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Aug 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Zhejiang Cancer Hospital
Data source: Zhejiang Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Hangzhou, China